Secondary progressive multiple sclerosis: new insights

BAC Cree, DL Arnold, J Chataway, T Chitnis, RJ Fox… - Neurology, 2021 - AAN Enterprises
In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by
insidious disability worsening that is independent from clinically apparent relapses and is …

Multiple sclerosis: clinical aspects

J Oh, A Vidal-Jordana, X Montalban - Current opinion in …, 2018 - journals.lww.com
A number of recent advances have been made in the clinical diagnosis and prognostication
of multiple sclerosis patients. Future research will enable the development of more accurate …

Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in …

L Kappos, JS Wolinsky, G Giovannoni… - JAMA …, 2020 - jamanetwork.com
Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …

Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis

C Tur, P Carbonell-Mirabent, Á Cobo-Calvo… - JAMA …, 2023 - jamanetwork.com
Importance Progression independent of relapse activity (PIRA) is the main event responsible
for irreversible disability accumulation in relapsing multiple sclerosis (MS). Objective To …

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis

JWL Brown, A Coles, D Horakova, E Havrdova… - Jama, 2019 - jamanetwork.com
Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Silent progression in disease activity–free relapsing multiple sclerosis

University of California, San Francisco MS … - Annals of …, 2019 - Wiley Online Library
Objective Rates of worsening and evolution to secondary progressive multiple sclerosis
(MS) may be substantially lower in actively treated patients compared to natural history …

Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis

C Barro, BC Healy, Y Liu, S Saxena… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - Springer
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

E Portaccio, A Bellinvia, M Fonderico, L Pastò… - Brain, 2022 - academic.oup.com
Disability accrual in multiple sclerosis may occur as relapse-associated worsening or
progression independent of relapse activity. The role of progression independent of relapse …

T helper cells: the modulators of inflammation in multiple sclerosis

M Kunkl, S Frascolla, C Amormino, E Volpe, L Tuosto - Cells, 2020 - mdpi.com
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the
progressive loss of axonal myelin in several areas of the central nervous system (CNS) that …